Table 3 Cath-lab medications and post-procedural clinical parameters
Variables | Total population | Propensity-matched population | ||||
|---|---|---|---|---|---|---|
Suboptimal flow (n = 245) | Optimal flow (n = 859) | P value | Suboptimal flow (n = 214) | Optimal flow (n = 214) | P value | |
Medications used during primary PCI | ||||||
Glycoprotein IIb/IIIa inhibitor, n (%) | 65 (26.5) | 99 (11.5) | < 0.001 | 56 (26.2) | 40 (18.7) | 0.098 |
IC Nitroprusside, n (%) | 37 (15.1) | 56 (6.5) | < 0.001 | 35 (16.4) | 5 (2.3) | < 0.001 |
IC Adrenaline, n (%) | 23 (9.4) | 28 (3.3) | < 0.001 | 18 (8.4) | 11 (5.1) | 0.178 |
Atropine, n (%) | 27 (11.0) | 72 (8.4) | 0.202 | 22 (10.3) | 26 (12.1) | 0.643 |
Noradrenaline, n (%) | 106 (43.3) | 128 (14.9) | < 0.001 | 91 (42.5) | 35 (16.4) | < 0.001 |
Post-procedural clinical parameters | ||||||
Creatine kinase peak, U/L, Median (IQR) | 5268 (3829.0–7422.0) | 4215 (2300.0–6409.0) | < 0.001 | 5265 (3829.0–7422.0) | 4542 (2156.3–6740.5) | 0.002 |
ST segment resolution, n (%) | ||||||
< 70% | 109 (44.5) | 315 (36.7) | 0.026 | 97 (45.3) | 80 (37.4) | 0.108 |
> 70% | 136 (55.5) | 544 (63.3) | 117 (54.7) | 134 (62.6) | ||
Mean Ejection Fraction (%) | 43.8 ± 6.2 | 46.2 ± 6.9 | < 0.001 | 43.71 ± 6.41 | 45.34 ± 7.48 | 0.015 |
Hospital stay (days), Median (IQR) | 4 (3–6) | 4 (3–5) | < 0.001 | 4 (3–6) | 4 (3–6) | 0.864 |